Intellia Therapeutics, Inc.
NTLA
|
$21.57
1.17%
1.16%
1.4M
|
Health Technology
(0.0% 1d) (-22.0% 1m) (-41.9% 1y) (1.2% 2d) (0.3% 3d) (-5.9% 7d) (27.22% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 2,080,180,775
http://www.intelliatx.com
Sec Filling | Patents | 270 employees
(US) Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
crispr genomic genome editing glass
add to watch list Paper trade email alert is off
Press-releases
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Published: 2024-03-21 (Crawled : 11:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.03%
H: 3.03%
C: 1.75%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.14%
H: 0.24%
C: 0.24%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 2.12%
H: 0.6%
C: -2.54%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 1.19%
H: 0.47%
C: -0.77%
meeting
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -2.42%
ntla-2001 first treatment therapeutics study
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
Published: 2024-02-15 (Crawled : 12:30) - globenewswire.com
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: -1.17%
H: 5.15%
C: 1.86%
fibrosis collaboration therapeutics
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 2.5%
H: 4.5%
C: 4.32%
conference company therapeutics
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Published: 2024-01-31 (Crawled : 22:00) - globenewswire.com
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 0.88%
H: 8.11%
C: 5.12%
ntla-2002 positive publication therapeutics
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
Published: 2024-01-24 (Crawled : 00:00) - biospace.com/
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 1.28%
H: 1.0%
C: -4.06%
spvn06 trial
Valo Health Announces Changes to its Board of Directors and Leadership Team
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.03%
H: 0.75%
C: 0.75%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: -2.62%
H: 2.9%
C: -1.23%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.81%
H: 0.63%
C: 0.3%
health
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.79%
H: 1.96%
C: 0.9%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: -2.34%
H: 0.45%
C: -0.69%
therapeutics
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 6.47%
H: 5.29%
C: 4.34%
ntla-2002 drug crispr designation therapeutics
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Published: 2023-11-09 (Crawled : 12:30) - globenewswire.com
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.89%
H: 0.15%
C: -1.87%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 0.18%
H: 0.67%
C: -12.42%
company therapeutics financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10